Loading patent…
AssigneeResearch Corporation Technologies, Inc.
InventorsBoris N. Afanasiev, Jonathan Ored Carlson, Barry J. Beaty, David R. Higgins, Kelly J. Thibault
Estimating the term…
The present invention is directed to use of Aedes aegypti densonucleosis virus (Aedes DNV or AeDNV) as a heterologous gene expression system. The invention described herein provides promoters from the Aedes aegypti genome such as the p.05, p7 and p61 promoters to generate expression vectors with cloning sites for insertion of heterologous genes. The invention further provides expression vectors comprising an AeDNV promoter operably linked to a heterologous gene and insect host cells comprising the vectors of the invention. Methods of producing recombinant proteins utilizing the vectors of the invention are also provided. The present invention further provides a kit containing the vectors of the invention for production of a recombinant protein.
A method of producing a recombinant protein comprising:
A compartmentalized kit for the production of a recombinant protein comprising a first container containing at least one of an expression vector comprising the 5' and 3'-termini of AeDNV genomic DNA flanking at least one expression cassette comprising an AeDNV promoter operably linked to a heterologous gene or an expression vector comprising the 5' and 3'-termini of AeDNV genomic DNA flanking at least one expression cassette comprising an AeDNV promoter and a cloning site wherein said cloning site is positioned relative to said promoter such that a heterologous gene inserted into said cloning site is operably linked to said promoter;
A compartmentalized kit for the production of a recombinant protein comprising at least one of an expression vector comprising the 5' and 3'-termini of AeDNV genomic DNA flanking at least one expression cassette comprising an AeDNV promoter operably linked to a heterologous gene or an expression vector comprising the 5' and 3'-termini of AeDNV genomic DNA flanking at least one expression cassette comprising an AeDNV promoter and a cloning site wherein said cloning site is positioned relative to said promoter such that a heterologous gene inserted into said cloning site is operably linked to said promoter, and a second container containing insect cells stably expressing AeDNV VP1 and VP2.
Dependencies are inferred from the claim text.